Crohn’s Disease | Current Treatment: Physician Insights | EU5 | 2017
MARKET OUTLOOK
There are multiple well-established therapies available to treat Crohn’s disease (CD). In particular, the mostly widely used biologics, the TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira), helped to advance CD treatment, especially for moderate to severe patients. Over the past two years, the CD treatment landscape has witnessed the approval of two novel biologics (i.e., Takeda’s Entyvio and Janssen’s Stelara) and the launch of biosimilar infliximab (e.g., Celltrion’s Remsima). Entyvio, the first and only cell adhesion molecule (CAM) inhibitor in the EU5, offers an alternative treatment for TNF-α refractory patients; the recent approval of Stelara for CD, the first-in-class IL-12/23 inhibitor, also further expands physicians’ treatment armamentarium. Indeed, the availability of these agents has influenced physicians’ prescribing behavior, and will continue to impact the treatment landscape.
QUESTIONS ANSWERED
- What drug classes are the patient share leaders across different lines of therapy? How are different biological agents positioned in surveyed physicians’ treatment algorithm?
- Under which scenarios do/will physicians prescribe Stelara?
- What are the common treatment scenarios before initiating the different biological agents (i.e., Remicade, Humira, biosimilar infliximab, Entyvio, Stelara)? What is the course of action upon discontinuing these biological agents?
- What factors drive therapy discontinuation and switch? What factors have/will drive recent/anticipated prescribing changes?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment paths, prescribing behaviors, and the factors and perceptions driving brand usage so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.
